ADAR1 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

ADAR1 Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72,500	Closed	-$2.92M	–	283
2026 Q1	$2.92M	Buy	72,500 +52,500	+263%	+$1.13M	0.17%	109
2025 Q4	$502K	Hold	20,000	–	–	0.04%	185
2025 Q3	$453K	Buy	20,000 +3,000	+18%	+$70K	0.04%	142
2025 Q2	$294K	Hold	17,000	–	–	0.05%	139
2025 Q1	$372K	Buy	17,000 +2,000	+13%	+$55.3K	0.07%	118
2024 Q4	$479K	Sell	15,000 -2,252	-13%	-$67.7K	0.1%	112
2024 Q3	$498K	Sell	17,252 -3,398	-16%	-$126K	0.08%	117
2024 Q2	$792K	Sell	20,650 -5,050	-20%	-$229K	0.15%	77
2024 Q1	$1.51M	Buy	+25,700	New	+$1.64M	0.34%	52

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ADAR1 Capital Management's APLS Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 72,500 shares — an estimated $2.92M sold.

ADAR1 Capital Management first reported a position in APLS in Q1 2024 and held it in 9 quarters. The position peaked at $2.92M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

ADAR1 Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 72,500 Apellis Pharmaceuticals shares in Q2 2026, an estimated $2.92M.
ADAR1 Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 9 quarters.
ADAR1 Capital Management's Apellis Pharmaceuticals position peaked at $2.92M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.